NGS-MRD across immunoglobulin rearrangements in pediatric B-ALL
Chen and colleagues evaluated IGH, IGK and IGL rearrangement-based MRD in a single-center pediatric B-ALL cohort. The study used Seq-MRD technology developed by ImmuQuad Biotech.
- Patients with NGS-MRD <0.01% at end of induction or <0.0001% at end of consolidation had 3-year event-free survival above 95% in this cohort.
- IGH-MRD was prognostic at end of induction and end of consolidation.
- At end of induction, NGS identified a higher-risk group among patients with flow-cytometry MRD below 0.01%.
